NRX Pharmaceuticals (NRXP) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed NRX Pharmaceuticals (NRXP) over the past year, gaining 3.0% versus a gain of 0.9%. Over five years, PDSB leads with a -92.5% price change compared with -96.8% for NRXP. PDS Biotechnology is the larger company by market cap ($95.4 million vs $95.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | PDSB |
|---|---|---|
| Share price | $2.15 | $0.7774 |
| Market cap | $95.31M | $95.39M |
| 1-day change | -15.69% | -3.70% |
| YTD return | -20.66% | +0.96% |
| 1-year return | +0.94% | +2.97% |
| 5-year return | -96.81% | -92.46% |
| EPS (TTM) | $-0.33 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.23M | — |
| Net income (latest FY) | $-28.62M | $-34.50M |
| Gross margin | 58.78% | — |
| Operating margin | -1324.41% | — |
| Net margin | -2336.49% | — |
| 52-week high | $5.06 | $1.79 |
| 52-week low | $1.62 | $0.195 |
| Distance from 52-week high | -57.47% | -56.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1702.33% | +478.85% |
| Average volume | 1.07M | 25.64M |
| Shares outstanding | 44.33M | 122.70M |
| Employees | 29 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NRXP vs PDSB FAQ
Which is bigger, NRX Pharmaceuticals or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $95.39M compared with $95.31M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, NRXP or PDSB?
PDSB returned +2.97% over the past 12 months, compared with +0.94% for NRXP (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.